Segment, Geographical and Other Revenue Information (Tables)

12 Months Ended

Dec. 31, 2019

Segment Reporting Information, Operating Income (Loss) [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):

	Year Ended December 31, 2019						Year Ended December 31, 2018
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	29,465	$	—	$	29,465	$	25,590	$	—	$	25,590
Research and development revenue	28,691		10,302		38,993		21,483		13,521		35,004
Total revenues	58,156		10,302		68,458		47,073		13,521		60,594
Costs and operating expenses:
Cost of product revenue	15,632		—		15,632		12,620		—		12,620
Research and development (1)	19,380		13,278		32,658		18,924		10,185		29,109
Selling, general and administrative(1)	8,462		2,222		10,684		7,538		771		8,309
Total segment costs and operating expenses	43,474		15,500		58,974		39,082		10,956		50,038
Income (loss) from operations	$	14,682	$	(5,198)	9,484		$	7,991	$	2,565	10,556
Corporate costs (2)					(19,624)						(20,324)
Depreciation and amortization					(1,778)						(1,147)
Loss before income taxes					$	(11,918)					$	(10,915)

⁽¹⁾ Research and development expenses and Selling, general and administrative expenses exclude depreciation and amortization of finance leases.

⁽²⁾ Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

	Year Ended December 31, 2018						Year Ended December 31, 2017
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	25,590	$	—	$	25,590	$	26,685	$	—	$	26,685
Research and development revenue	21,483		13,521		35,004		15,648		7,691		23,339
Total revenues	47,073		13,521		60,594		42,333		7,691		50,024
Costs and operating expenses:
Cost of product revenue	12,620		—		12,620		14,327		—		14,327
Research and development (1)	18,924		10,185		29,109		16,847		12,107		28,954
Selling, general and administrative(1)	7,538		771		8,309		7,371		—		7,371
Total segment costs and operating expenses	39,082		10,956		50,038		38,545		12,107		50,652
Income (loss) from operations	$	7,991	$	2,565	10,556		$	3,788	$	(4,416)	(628)
Corporate costs (2)					(20,324)						(21,245)
Depreciation					(1,147)						(1,042)
Loss before income taxes					$	(10,915)					$	(22,915)

⁽¹⁾ Research and development expenses and Selling, general and administrative expenses exclude depreciation.

⁽²⁾ Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

The following table provides stock-based compensation expense included in income (loss) from operations by segment (in thousands):

Schedules of Concentration of Risk

Customers that each contributed 10% or more of our total revenues were as follows:

	Percentage of Total Revenues For The Years Ended December 31,
	2019		2018		2017
Merck	28	%	29	%	28	%
Novartis	23	%	*		14	%
Nestlé Health Science	15	%	22	%	15	%
Tate & Lyle	*		13	%	11	%

* Percentage was less than 10%

Customers that each accounted for 10% or more of our accounts receivable balance for the period presented were as follows:

	Percentage of Accounts Receivables As Of December 31,
	2019		2018
Merck & Co.	38	%	37	%
Nestlé Health Science	10	%	17	%
Novartis	*		11	%
Kyorin Pharmaceutical Co Ltd	*		16	%

* Percentage was less than 10%

Schedule of Revenues by Geographical Area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):

	Year Ended December 31,
	2019		2018		2017
Revenues
Americas	$	13,039	$	15,370	$	15,575
EMEA	37,133		22,361		19,610
APAC	18,286		22,863		14,839
Total revenues	$	68,458	$	60,594	$	50,024

Schedule of Long-lived Assets by Geographical Area

Identifiable long-lived assets by location and goodwill by reporting unit as of year-end were as follows (in thousands):

	December 31,
	2019		2018
Long-lived assets
United States	$	6,282	$	4,759

Schedule of Goodwill

	Year Ended December 31, 2019						Year Ended December 31, 2018
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Goodwill	$	2,463	$	778	$	3,241	$	2,463	$	778	$	3,241